OncoMatch/Clinical Trials/NCT06898970
Intratumoral Vusolimogene Oderparepvec (VO) in Combination With Pembrolizumab for Angiosarcoma
Is NCT06898970 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Vusolimogene Oderparepvec (VO) and Pembrolizumab for angiosarcoma.
Treatment: Vusolimogene Oderparepvec (VO) · Pembrolizumab — This is a multicenter, open-label study of Intratumoral Vusolimogene Oderparepvec (VO) to investigate safety and estimate when used in combination with pembrolizumab for treating participants with angiosarcoma. This is the first study evaluating this novel combination in participants with advanced angiosarcoma who have progressed after prior immunotherapy.
Check if I qualifyExtracted eligibility criteria
Cancer type
Sarcoma
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: immunotherapy
has received and progressed on at least one prior immunotherapy based regimen within 6 months prior to screening
Must have received: taxane — first-line
must have received and progressed following first-line standard of care, including a taxane or anthracycline based chemotherapy regimen
Must have received: anthracycline — first-line
must have received and progressed following first-line standard of care, including a taxane or anthracycline based chemotherapy regimen
Cannot have received: oncolytic therapy
Prior treatment with an oncolytic therapy
Lab requirements
Blood counts
WBC >= 2.0 × 10^9/L; ANC >= 1.5 × 10^9/L; Platelet count >=100 × 10^9/L; Hemoglobin >= 9 g/dL or >= 5.6 mmol/L (without erythropoietin dependency and without pRBC transfusion within 2 weeks of dosing)
Kidney function
Blood creatinine <= 1.5 × ULN or measured/calculated creatinine clearance >= 30 mL/min for participants with creatinine > 1.5 × institutional ULN
Liver function
Total bilirubin <= 1.5 × ULN (except Gilbert Syndrome < 3.0 × ULN) or direct bilirubin <= ULN if total bilirubin > 1.5 × ULN; if total bilirubin > 1.5 × ULN but <= 3 × ULN, AST and ALT <= 3 × ULN; AST and ALT <= 3.0 × ULN (or <= 5.0 × ULN, if liver metastases); if AST/ALT > 3 × ULN but <= 5 × ULN, total bilirubin must be <= 1.5 × ULN; ALP <= 2.5 × ULN (or <= 5.0 × ULN, if liver or bone metastases)
Adequate hematologic function including: ... Adequate hepatic function including: ... Adequate renal function: ... Adequate coagulation: PT or INR <=1.5 × ULN, and PTT or aPTT <= 1.5 × ULN. For participants on chronic anticoagulant therapy, pretreatment INR < 2.5. Adequate oxygen saturation: >=92% on room air.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of California, San Francisco · San Francisco, California
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify